Sagimet Biosciences (SGMT) Accumulated Expenses (2022 - 2026)

Sagimet Biosciences' Accumulated Expenses history runs 5 years deep, the most recent figure standing at $3.0 million for Q1 2026.

• In Q1 2026, Accumulated Expenses rose 344.36% year-over-year to $3.0 million; the TTM figure through Mar 2026 stood at $3.0 million (up 344.36% YoY), while the FY2025 annual figure was $3.7 million, up 173.49% from the prior year.
• Accumulated Expenses was $3.0 million for Q1 2026 at Sagimet Biosciences, down from $3.7 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $5.4 million in Q4 2023 to a low of $109000.0 in Q3 2025.
• Historically, Accumulated Expenses has averaged $2.7 million across 5 years, with a median of $3.0 million in 2026.
• The sharpest annual moves came in 2025 and 2026: Accumulated Expenses tumbled 86.61% in 2025, then surged 344.36% in 2026.
• A 5-year view of Accumulated Expenses shows it stood at $4.0 million in 2022, then jumped by 34.37% to $5.4 million in 2023, then plunged by 74.87% to $1.4 million in 2024, then soared by 173.49% to $3.7 million in 2025, then retreated by 20.44% to $3.0 million in 2026.
• The last three Accumulated Expenses figures came in at $3.0 million (Q1 2026), $3.7 million (Q4 2025), and $109000.0 (Q3 2025), per Business Quant data.